| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other (expense), net | -140 | -999 | -2,414 | -100 |
| Loss before income taxes | -52,793 | -46,295 | -49,418 | -43,985 |
| Provision for income taxes | 111 | 337 | 80 | -344 |
| Net loss | -52,904 | -46,632 | -49,498 | -43,641 |
| Accrued dividends on convertible preferred stock | 1,375 | 1,349 | 1,322 | 1,329 |
| Net loss attributable to common stockholders | -54,279 | -47,981 | -50,820 | -44,970 |
| Earnings per share, basic | -0.82 | -0.75 | -0.81 | -0.73 |
| Earnings per share, diluted | -0.82 | -0.75 | -0.81 | -0.73 |
| Weighted average number of shares outstanding, basic | 66,261,055 | 63,684,359 | 63,059,165 | 61,219,918 |
| Weighted average number of shares outstanding, diluted | 66,261,055 | 63,684,359 | 63,059,165 | 61,219,918 |
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)